序号股东名称持股比例1熠保科技（上海）有限公司100% 天眼查显示，近日，云南熠保医疗科技有限公司成立，法定代表人为罗晗，注册资本300万人民币，由 熠保科技（上海）有限公司全资持股。 企业名称云南熠保医疗科技有限公司法定代表人罗晗注册资本300万人民币国标行业科学研究和技术服 务业>研究和试验发展>工程和技术研究和试验发展地址云南省昆明市五华区丰宁街道办事处虹山南路 社区虹山南路30号1层企业类型有限责任公司（法人独资）营业期限2025-12-24至无固定期限登记机关 五华区市场监督管理局 来源：市场资讯 经营范围含医学研究和试验发展；技术服务、技术开发、技术咨询、技术交流、技术转让、技术推广； 互联网数据服务；企业管理咨询；信息咨询服务（不含许可类信息咨询服务）；信息系统集成服务；电 子产品销售；通讯设备销售；计算机软硬件及辅助设备批发；计算机软硬件及辅助设备零售；软件开 发；数据处理服务；广告设计、代理；广告发布；广告制作；互联网销售（除销售需要许可的商品）； 城市绿化管理；规划设计管理；人工智能通用应用系统；体育健康服务；远程健康管理服务；健康咨询 服务（不含诊疗服务）。（除依法须经批准的项目外，凭营 ...

Core Insights - The second "Haiyi Hui Medical Technology Innovation Ecosystem Conference" was held in Beijing, focusing on AI and technology's role in advancing healthcare in China by 2030 [1] - The conference aimed to address the low medical achievement conversion rate in China, which has been below 8%, highlighting the need for collaboration across research, clinical validation, and industrial transformation [2][3] Group 1: Medical Innovation and Collaboration - The establishment of Haiyi Hui aims to create a collaborative platform for medical and industrial transformation, linking over 100 research institutions and hospitals to conduct more than 600 distributed clinical trials [2] - The conference emphasized the importance of aligning research with clinical needs to overcome barriers in the medical innovation process [3] - A call for an open and collaborative mechanism was made to break down barriers in data, disciplines, and institutions, ensuring a free flow of innovative resources [2] Group 2: Accelerating Technology Transfer - The conference highlighted the need for a transformation system that integrates enterprises, clinical needs, and deep collaboration between academia and industry to enhance the speed of technology transfer [4] - Haiyi Hui announced over ten groundbreaking technologies in various fields, showcasing a complete cycle from technological breakthroughs to clinical application [5] - The integration of AI in healthcare is seen as a key driver for enhancing service accessibility, precision, and efficiency [6] Group 3: Talent Development and Social Responsibility - Haiyi Hui has initiated a "Science and Technology Elite Cultivation Program" to support young researchers and innovation teams, focusing on rare and difficult diseases [7] - The program aims to build a collaborative training system that connects basic research, clinical practice, and technology transfer [7] - The establishment of the "China Youth Entrepreneurship and Employment Foundation" aims to strengthen the cultivation of composite talents in the healthcare sector [7] Group 4: Strategic Vision and Future Directions - Haiyi Hui is exploring pathways to drive medical industrial transformation through ecological forces and AI integration for high-quality development in the health industry [8] - The platform has established mechanisms for integrating clinical, research, and industrial efforts, as well as channels for technology, capital, and market transformation [9] - The future of medical innovation is viewed as a success of the ecosystem rather than individual technologies, with aspirations to integrate into a larger domestic and international cycle [9]

Core Points - The company has approved the addition and revision of internal management systems to enhance operational standards and governance structure [1][22] - The company plans to appoint Zhonghui Certified Public Accountants as its financial and internal control audit institution for the year 2025 [5][23] Group 1: Internal Management System Updates - The company held its 37th meeting of the fourth board of directors on November 24, 2025, where it approved the addition of the "Management System for the Departure of Directors and Senior Management" and revisions to existing internal management systems [1][22] - The revised "Selection System for Accounting Firms" has been approved by the board's audit committee [2][22] - The "Financing Decision-Making System" will require approval from the shareholders' meeting [3][22] Group 2: Audit Institution Appointment - The company intends to continue employing Zhonghui Certified Public Accountants as its financial and internal control audit institution for 2025, pending approval from the shareholders' meeting [5][23] - Zhonghui Certified Public Accountants has a history of providing securities services and has been operational since December 2013, with a total revenue of 1.01434 billion yuan in 2024, of which 899.48 million yuan was from audit services [6][7][8] - The audit fees for 2025 are capped at 900,000 yuan, with 700,000 yuan allocated for financial audit and 200,000 yuan for internal control audit, reflecting a change of less than 20% from the previous year [14][24]

Core Viewpoint - The China Securities Regulatory Commission (CSRC) has requested additional documentation from Weimai regarding its overseas listing application, focusing on employee stock ownership plans and foreign exchange registration procedures [1][2][3] Group 1: Regulatory Requirements - CSRC has asked Weimai to clarify the foreign investment and foreign exchange management procedures related to its subsidiaries, including Qiushi Technology and others [1] - The commission requires a detailed explanation of the acquisition costs, pricing basis, and tax obligations related to the purchase of various companies, including Hangzhou Weir and Ronghai Insurance [1][2] - Weimai must provide information on its employee incentive programs, including the involvement of external consultants and the establishment of employee stock ownership platforms [2] Group 2: Company Overview - Weimai is recognized as a pioneer and leader in AI-driven full-cycle management services in China, linking hospitals, doctors, and patients to enhance the healthcare service value chain [3] - According to projected revenues for 2024, Weimai ranks among the top three full-cycle management service providers in China and is the largest patient-oriented AI-enabled service provider [3] - The company's services encompass the entire health management process for patients, from pre-treatment to post-treatment [3]

Summary of Key Points Core Viewpoint - 医渡科技 has been actively repurchasing its shares, indicating confidence in its market position and future prospects [1] Group 1: Share Buyback Activity - On October 17, 医渡科技 spent HKD 1.013 million to repurchase 181,000 shares [1] - This week, the company has conducted three buybacks totaling approximately 2.685 million shares, with a total expenditure exceeding HKD 15.6 million [1] - Since September 26, the company has executed five buybacks, amounting to around 3.373 million shares and nearly HKD 20 million in total [1] Group 2: Southbound Capital Inflows - On October 14, southbound funds net purchased HKD 34.7273 million worth of 医渡科技 shares, marking the highest net inflow since September 1, 2025 [1] - The net buying has continued for three consecutive days, with a cumulative net purchase of HKD 57.79 million [1] Group 3: Product Development and Market Support - Recently, the world's first topical treatment for proliferative superficial infantile hemangioma, Timolol Maleate Gel, has been approved for market release [1] - 医渡科技 provided critical market research and project analysis services that supported the drug's development and market entry [1]

Core Viewpoint - The event focused on the globalization of medical innovation in China, highlighting the integration of AI in healthcare services and the transformation of the industry towards efficiency-driven competition [1][6]. Group 1: AI Integration in Healthcare - Huamei Haolian positions itself as a "one-stop AI digital healthcare service platform," aiming to efficiently integrate medical resource supply and demand through a B2B2C model [2]. - The company emphasizes a "data-driven service upgrade" approach, showcasing a development trend of "point - line - network" in healthcare services [3]. - AI has significantly improved efficiency in report interpretation, reducing the time from approximately 6 hours per case to under 30 minutes through an "AI + human professional review" model [2][3]. Group 2: Comprehensive Health Management - AI extends to full-cycle health management, transforming user health data into understandable content and providing personalized intervention suggestions for chronic disease patients [3]. - The "Dr. Hua" AI system is central to creating a closed-loop service ecosystem, automatically matching users with appropriate healthcare providers based on their needs [3]. - The integration of AI allows for compliance in sharing health data, facilitating value collaboration among healthcare, insurance, and users [3]. Group 3: Driving Value through Collaboration - AI acts as a "demand detector" in service innovation, identifying industry pain points and automating standard service processes to respond quickly to healthcare needs [5]. - In service delivery, AI matches users with healthcare professionals based on health records and needs, significantly reducing wait times and enhancing service accessibility [5]. - The long-term goal is to create a "data-driven ecological barrier" that empowers healthcare institutions and partners while ensuring technology is effectively applied in various scenarios [5]. Group 4: Industry Transformation and Future Outlook - AI is shifting the healthcare service industry from a focus on resource competition to efficiency competition, promoting quality over quantity [6]. - Companies that can effectively implement AI in practical scenarios are expected to emerge as core players, while those relying on low-cost strategies may be eliminated [6]. - The future vision for AI in healthcare is to serve as a "connecting link," breaking down barriers between service segments and enabling personalized healthcare experiences for individuals [6].

Core Viewpoint - Meis Health (02415) announced that its subsidiary, Shanghai Meis Pharmaceutical Technology Co., Ltd., has won a large real-world research project from a Chinese pharmaceutical company, focusing on the efficacy and safety of IL-1β monoclonal antibody treatment for patients with acute and intercritical gout, with a project value of approximately RMB 21 million [1] Group 1 - The project aims to systematically evaluate the effectiveness and safety of IL-1β monoclonal antibody treatment through a combination of prospective and retrospective observational studies [1] - The company leverages over a decade of experience in its internet doctor platform, utilizing big data and artificial intelligence technologies to connect doctors, patients, and medical device companies [1] - The digital solutions provided by the company aim to empower the healthcare ecosystem and improve the quality of medical services [1]

Core Viewpoint - Mees Health (02415.HK) announced that its subsidiary, Shanghai Mees Pharmaceutical Technology Co., Ltd., has won a large real-world research project from a Chinese pharmaceutical company, focusing on the efficacy and safety of IL-1β monoclonal antibody treatment for gout patients [1] Group 1 - The project aims to systematically evaluate the effectiveness and safety of IL-1β monoclonal antibody treatment for patients during both acute and intercritical phases of gout through a combination of prospective and retrospective observational studies [1] - The project is valued at approximately RMB 21 million [1] - The group leverages over a decade of experience in its internet doctor platform, utilizing big data and artificial intelligence technologies to connect doctors, patients, and medical device companies, thereby providing digital solutions to enhance the healthcare ecosystem and improve medical quality [1]

Core Viewpoint - Mees Health (02415) announced that its subsidiary, Shanghai Mees Pharmaceutical Technology Co., Ltd., has won a large real-world research project from a Chinese pharmaceutical company, focusing on the efficacy and safety of IL-1β monoclonal antibody treatment for acute and intercritical gout patients [1] Group 1 - The project amount is approximately RMB 21 million [1] - The project aims to systematically evaluate the effectiveness and safety of the treatment through a combination of prospective and retrospective observational studies [1] Group 2 - The company leverages over ten years of experience in its internet doctor platform, utilizing big data and artificial intelligence technologies to connect doctors, patients, and medical device companies [1] - The digital solutions provided by the company aim to empower the medical ecosystem and improve healthcare quality [1]

Core Viewpoint - Yidu Technology (2158.HK) shares increased by 5.91% to HKD 6.09 following the announcement of a significant project win in clinical research [1] Group 1: Company Developments - Yidu Technology's affiliate, Tianjin Happy Life Technology Co., Ltd., won a bid for the Phase III clinical research project of the human nerve growth factor (SMR001) eye drops from Shandong Yandu Biotechnology Co., Ltd. The total project amount is approximately CNY 55.82 million [1] - The company utilizes its proprietary core algorithm engine, YiduCore, to create a "data-algorithm-scenario" closed-loop system, enabling efficient innovation and low-cost scalable applications of AI technology [1] Group 2: Industry Impact - The implementation of AI technology is driving intelligent decision-making across the entire healthcare ecosystem, which includes medicine, pharmaceuticals, insurance, and patients [1]